Menquadfi Administration and Contraindications
Menquadfi (MenACWY-TT) is administered as a single 0.5 mL intramuscular injection, with dosing schedules varying by age: infants starting at 6 weeks receive a 4-dose series (2,4,6, and 12-18 months), while individuals ≥2 years receive a single dose. 1
Administration Details
Route and Preparation
- Intramuscular injection only - 0.5 mL dose 1
- Inspect visually before administration - should be clear and colorless
- Do not administer if particulate matter or discoloration is present 1
- Key advantage: Ready-to-use liquid formulation requiring no reconstitution, reducing administration errors 2, 3
Age-Specific Dosing Schedules
Infants 6 weeks to <6 months:
- 4-dose series at 2,4,6, and 12-18 months
- First dose may be given as early as 6 weeks 1
Infants 6-11 months:
- 2-dose series with second dose in the second year of life, at least 3 months after first dose 1
Infants 12-23 months:
- 2-dose series with second dose at least 3 months after first dose 1
Individuals ≥2 years:
- Single dose for primary vaccination 1
Booster vaccination:
- Single dose for individuals ≥13 years at continued risk
- Must be at least 3 years since prior meningococcal ACWY conjugate vaccine 1
Following polysaccharide vaccine:
- Single dose if at least 3 years have elapsed since prior meningococcal polysaccharide vaccine 1
Absolute Contraindications
Do not administer Menquadfi if:
- Severe allergic reaction to any vaccine component 1
- Previous severe allergic reaction to any dose of Menquadfi 1
- Previous severe allergic reaction to any tetanus toxoid-containing vaccine 1
This last contraindication is critical because Menquadfi uses tetanus toxoid as the conjugate carrier protein, distinguishing it from other meningococcal vaccines that use CRM197 (diphtheria protein) or diphtheria toxoid.
Critical Warnings and Precautions
Immediate Management Requirements
- Anaphylaxis preparedness mandatory: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions 1
- Syncope protocols: Procedures must be in place to prevent injury from fainting, which can occur with any injectable vaccine 1
Special Populations Requiring Caution
Immunocompromised individuals:
- May have reduced immune responses, including those on immunosuppressant therapy 1
- Complement deficiency patients remain at risk: Even with vaccination, persons with complement deficiencies or receiving complement inhibitors (eculizumab, ravulizumab) remain at increased risk for invasive meningococcal disease 1
- For these high-risk patients, ACIP recommends a 2-dose primary series ≥8 weeks apart (not the standard single dose) 4
Guillain-Barré Syndrome (GBS) history:
- GBS has been reported temporally following other meningococcal conjugate vaccines
- Clinical decision-making required: Weigh expected benefits against potential risks in patients with prior GBS 1
- This is not an absolute contraindication but requires careful consideration
Important Limitations
Does not protect against serogroup B:
- Menquadfi only covers serogroups A, C, W, and Y
- Does NOT prevent N. meningitidis serogroup B disease 1
- Separate serogroup B vaccination needed for comprehensive protection
Not a substitute for tetanus immunization:
- Despite containing tetanus toxoid as carrier protein, does not replace routine tetanus vaccination 1
May not protect all recipients:
- Vaccination may not protect 100% of vaccine recipients 1
Practical Considerations for High-Risk Groups
According to ACIP guidelines, certain populations require modified schedules 4:
Complement deficiency/complement inhibitor use:
- 2-dose primary series ≥8 weeks apart (ages ≥10 years)
- Boosters every 5 years if risk continues 4
Functional or anatomic asplenia:
- Similar 2-dose primary series recommended
- Boosters every 5 years 4
The ready-to-use liquid formulation is a significant practical advantage over vaccines requiring reconstitution, reducing preparation time and eliminating reconstitution errors 2, 3.